If you’ve been following recent conversations around substance use, you may have heard that the street drug supply is changing quickly. In my work at Donlan Counseling Services, clients have been describing shifts in how substances feel and behave—often before these trends reach wider awareness.
Two emerging concerns—medetomidine in fentanyl and a newer adulterant called BTMPS—are important for individuals, families, and professionals to understand. These changes are directly affecting overdose risk, response, and overall safety. Notably, they are also part of a broader transition: these substances are increasingly replacing xylazine, which had previously become widespread in the illicit fentanyl supply.
From Xylazine to Medetomidine: A Concerning Shift
Over the past few years, xylazine (often referred to as “tranq”) became a common additive in fentanyl. Like medetomidine, it is a veterinary sedative and not an opioid, which made overdoses more difficult to reverse with naloxone alone.
Now, emerging data and clinical reports suggest that medetomidine may be phasing in as xylazine phases out in some drug markets.
This matters because:
- The pattern of non-opioid sedatives mixed with fentanyl is continuing, not disappearing
- Medetomidine may produce similar or even more profound sedation
- The same concerns seen with xylazine—limited response to naloxone and prolonged unconsciousness—are still present
In other words, while the specific substance may be changing, the underlying risk profile remains—and may be intensifying.
What Is Medetomidine and Why Is It Showing Up in Fentanyl?
Medetomidine is a powerful veterinary sedative (an alpha-2 adrenergic agonist) that is not approved for human use. It has recently been detected in the illicit drug supply, particularly in fentanyl and other opioids.
This is a significant public health concern because medetomidine is not an opioid.
That means:
- Naloxone (Narcan) may not fully reverse an overdose if medetomidine is involved
- Individuals may remain heavily sedated or unresponsive even after naloxone is given
- The overall presentation of overdose becomes more complex and harder to recognize
From a clinical perspective, this changes how overdoses look in real-world situations. Instead of a typical opioid overdose that responds clearly to naloxone, we may see partial responses, prolonged sedation, or delayed recovery.
Clients have described this as:
- “Heavier than usual”
- “Harder to wake up from”
- “Not like a normal fentanyl high”
These reports are consistent with what we would expect based on medetomidine’s pharmacological effects.
BTMPS is an emerging adulterant found in fentanyl that is not yet well understood in terms of human health effects. It has been identified through drug-checking and forensic analysis, raising concerns about fentanyl contamination trends in 2026.
The main issue with BTMPS is uncertainty.
Current concerns include:
- Unknown toxicity in humans
- Unpredictable physical and psychological effects
- Increased variability in drug potency and experience
Unlike substances that are more widely studied, BTMPS introduces a layer of risk that users cannot easily anticipate or manage.
Some individuals report:
- Unexpected anxiety or agitation
- Physical discomfort that differs from opioid effects
- A general sense that the substance feels “off”
While research is still developing, these patterns suggest that BTMPS may be contributing to atypical or mixed drug reactions.
Why These Drug Trends Matter Now
The presence of medetomidine and BTMPS—and the shift away from xylazine toward new sedative additives—points to a larger pattern: the illicit fentanyl supply is becoming more complex and less predictable.
For individuals who use substances, this means:
- Prior tolerance may no longer predict safe dosing
- The risk of overdose increases, even with familiar sources
- It becomes harder to recognize when something is wrong
- Emergency responses may need to be faster and more persistent
Even experienced users are finding that their expectations no longer match reality. From a counseling perspective, this often leads to increased anxiety, loss of confidence in managing use, and, in some cases, a renewed openness to change.
Harm Reduction Strategies for a Changing Drug Supply
In the context of fentanyl contamination and emerging drug additives, harm reduction remains critical:
- Assume polysubstance exposure (multiple substances in one sample)
- Carry naloxone (Narcan) and be prepared to use multiple doses
- Do not use alone, or use services/strategies that allow someone to check on you
- Watch for unusual symptoms, not just typical opioid overdose signs
- Call emergency services if someone is unresponsive or not improving
These steps are especially important as substances like medetomidine complicate overdose reversal.
A Clinical Perspective from Donlan Counseling Services
In practice, these emerging drug trends are already impacting how clients think about substance use. Some are expressing concern about safety in ways they hadn’t before. Others feel unsettled by the unpredictability of what they’re using.
Clear, accurate information plays an important role here.
When people understand what’s changing in the drug supply, they are better equipped to:
- Make informed decisions
- Reduce risk
- Consider next steps, whether that involves safer use, reduction, or treatment
Final Thoughts: Staying Informed Saves Lives
The conversation around fentanyl adulterants, medetomidine risks, BTMPS, and the decline of xylazine is still evolving. Awareness, however, is one of the most effective tools we have right now.
If you or someone you care about is affected by substance use, you don’t have to navigate this alone.